A two-arm, randomised, assessor-blind, parallel group study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) and Relvar Ellipta DPI on ventilation heterogeneity in subjects with partially controlled or uncontrolled asthma.

Trial Profile

A two-arm, randomised, assessor-blind, parallel group study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) and Relvar Ellipta DPI on ventilation heterogeneity in subjects with partially controlled or uncontrolled asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary) ; Vilanterol/fluticasone furoate
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Mundipharma Research
  • Most Recent Events

    • 18 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Aug 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top